

22 DEC 2005

PATENT COOPERATION TREATY

PC1/EP2003/012117

Translation

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

	(1 C1 7 H H O O		
Applicant's or agent's file reference LTS 2002/006 PCT	FOR FURTHER AC		eation of Transmittal of International Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP2003/012117	International filing dat 31 October 2003	, ,	Priority date (day/month/year) 13 November 2002 (13.11.2002)
International Patent Classification (IPC) or na A61L 15/58	itional classification and	d IPC	
Applicant LTS	LOHMANN THER	RAPIE-SYSTEME	AG
and is transmitted to the applicant acc. 2. This REPORT consists of a total of	5 sheets, ed by ANNEXES, i.e., s this report and/or sheet Administrative Instruction	including this cover shape of the description is containing rectifications under the PCT).	neet. on, claims and/or drawings which have been the made before this Authority (see Rule
IV Lack of unity of inve V Reasoned statement of citations and explana VI Certain documents of the Certain defects in the	ention under Article 35(2) with tions supporting such st	n regard to novelty, invitatement	p and industrial applicability ventive step or industrial applicability;
Date of submission of the demand 10 March 2004 (10.03.2)	2004)	Date of completion of	f this report bruary 2005 (16.02.2005)
Name and mailing address of the IPEA/EP Facsimile No.		Authorized officer Telephone No.	

International application No. PCT/EP2003/012117

I. Ba	sis of the r	eport
1. W	ith regard t	to the elements of the international application:*
] the inte	emational application as originally filed
\boxtimes	the des	scription:
	pages	1-14 , as originally filed
	pages	, filed with the demand
	pages	, filed with the letter of
\triangleright	the clai	
<u>-</u>	pages	, as originally filed
	pages	, as amended (together with any statement under Article 19
	pages	, filed with the demand
	pages	1-18 , filed with the letter of07 December 2004 (07.12.2004)
Г	7 the dra	awings:
<u> </u>	pages	and the little of the
	pages	, as originally filed, filed with the demand
	pages	, filed with the letter of
	¬	ence listing part of the description:
L.,	the seque pages	
	pages	, as originally filed
	pages	, filed with the demand, filed with the demand
200		
the	e internation nese elemen	to the language, all the elements marked above were available or furnished to this Authority in the language in which nal application was filed, unless otherwise indicated under this item. ats were available or furnished to this Authority in the following language which is:
L		guage of a translation furnished for the purposes of international search (under Rule 23.1(b)).
Ļ	-	aguage of publication of the international application (under Rule 48.3(b)).
L	the lan or 55.3	nguage of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/3).
3. W	ith regard eliminary e	to any nucleotide and/or amino acid sequence disclosed in the international application, the international examination was carried out on the basis of the sequence listing:
Ļ	contair	ned in the international application in written form.
Ļ	filed to	ogether with the international application in computer readable form.
Ļ	7	ned subsequently to this Authority in written form.
L	7	ned subsequently to this Authority in computer readable form.
L	interna	tatement that the subsequently furnished written sequence listing does not go beyond the disclosure in the ational application as filed has been furnished.
L.		atement that the information recorded in computer readable form is identical to the written sequence listing has urnished.
4.		nendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos
		the drawings, sheets/fig
5. [This rep	port has been established as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
in	placement s this report d 70.17).	sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to t as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16
		ent sheet containing such amendments must be referred to under item 1 and annexed to this report.

International application No. PCT/EP 03/12117

I.	Basi	s of	the	re	po	rt
----	------	------	-----	----	----	----

1. This report has been drawn on the basis of (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):

The new set of claims submitted with the letter of 2

December 2004 meets the requirements of PCT Article 19(2)

because the content of claims 1-18 does not go beyond the disclosure in the international application as filed.

International application No. PCT/EP 03/12117

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability
	citations and explanations supporting such statement

Statement			
Novelty (N)	Claims	4-5, 7-8, 11-12	YES
	Claims	1-3, 6, 9-10, 13-18	_ NO
Inventive step (IS)	Claims		YES
	Claims	4-5, 7-8, 11-12	_ NO
Industrial applicability (IA)	Claims	1-18	YES
	Claims		NO

2. Citations and explanations

The numbering of the documents is the same as in the search report.

1 Novelty

The content of claims 1-3, 6, 9-10 and 13-18 is not novel within the meaning of PCT Article 33(2).

Document D2 already describes a hot-melt extruded film for the transdermal or mucosal administration of active substances, whose adhesive force develops after humidification (see column 5, lines 3-15). A film for the treatment of wounds contains, inter alia, hydroxypropyl cellulose, polyvinyl pyrrolidone, carbomer and polycarbophil, and can be connected to an overlaying adhesive patch (see example 4). A vitamin E adhesive patch against wrinkles and senile lentigo contains, inter alia, Gantrez MS-955, polycarbophil and hydroxypropyl cellulose (see example 7). The bioadhesive film also contains organic acids such as tartaric acid (see claim 1 and example 7).

Consequently, the subject matter of claims 1-3, 6, 9-10 and 13-18 is not novel.

2 Inventive step

The subject matter of claims 4-5, 7-8 and 11-12 does not involve an inventive step within the meaning of PCT Article 33(3).

The problem to be solved by the application is that of providing an adhesive for medical adhesive patches, which has improved adhesive properties on a moist substrate.

The solution describes the combination of a copolymer of methylvinyl ether and maleic acid anhydride (PVM/MA copolymer, Gantrez AN) with polyvinyl alcohol, a film-forming polyacrylate such as Eudragit NE 40 D or a pressure sensitive polyacrylate adhesive such as Duro-Tak. Instead of Gantrez AN the acid form of the anhydride can also be used (Gantrez S).

Document D3 is the closest prior art. Claim 3 of document D3 lists a number of polymers which can be used alone or in combination to produce moisture-activated adhesive layers. This list also comprises, inter alia, PVM/MA copolymers and polyvinyl alcohols. The examples show that combinations of, for example, Gantrez S-97 with polyvinyl pyrrolidone (example 6) or polyvinyl alcohol with polyvinyl pyrrolidone (example 1) have the desired adhesive force on a moist substrate. A person skilled in the art would therefore be motivated to combine polymers specified in the list for the production of an

adhesive layer because he can expect this to be successful. Consequently, the content of claim 8 cannot be considered inventive because it was not found to have a surprising effect. An analogous argument applies to the subject matter of claim 12. Claim 30 of document D2 lists adhesive polymers used in moisture-activated adhesive layers. These include, inter alia, PVM/MA copolymers and acrylic polymers.

For the Examining Authority to be able to recognize an inventive step, the applicant is kindly requested to submit data which show that the present formulation has improved properties with respect to the prior art.

3 Industrial applicability

The subject matter of claims 1-18 is industrially applicable within the meaning of PCT Article 33(4).